IntelGenx Technologies Corp. (IGXT) Research

IntelGenx Technologies Corp. operates as a specialized drug delivery firm, concentrating on the creation and production of innovative oral thin film products for the pharmaceutical industry. Their current portfolio features several oral film formulations: INT0008/2008, a Rizatriptan product addressing migraine headaches; INT0046/2018, intended for adult applications; INT0007/2006, developed for the treatment of erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, aimed at combating opioid addiction; INT0010/2006, designed to alleviate neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film for schizophrenia or bipolar 1 disorder; and INT0048/2020, catering to animal health. Furthermore, IntelGenx is advancing additional projects in its development pipeline, specifically INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established various agreements, including licensing, development, and supply arrangements with Tilray, Inc., alongside a development partnership with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.

Open IntelGenx Technologies Corp. (IGXT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.